Literature DB >> 8325955

Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.

E M Wallace1, S M Gow, F C Wu.   

Abstract

Sex-steroid based male contraceptive regimes induce azoospermia in only 40-70% of Caucasian men. The reason(s) why the remainder maintains a low level of spermatogenesis (oligozoospermia) despite gonadotrophin suppression is unclear. In order to improve our understanding of this phenomenon, we examined the changes in sperm density and plasma LH, FSH, testosterone (T), oestradiol (E2), and inhibin (IN) in 28 normal men who received 200 mg testosterone enanthate (TE) im weekly during a male contraceptive efficacy trial. Gonadotrophins were measured by an ultrasensitive time-resolved immunofluorometric assay (DELFIA) with a sensitivity of 0.04 U/L, to determine the adequacy of suppression. Seventeen of the 28 men achieved azoospermia; the other 11 remained oligozoospermic (sperm density 3.3-4.7 x 10(6)/mL) after 6 months of TE exposure. Azoospermic subjects displayed a more rapid decline in sperm density, a significant difference being apparent by 5 weeks after starting TE. During TE treatment, both LH and FSH were consistently suppressed to below the limits of detection, whereas there was a 2.5-fold rise in T and E2 with a similar decrease in IN. There were no consistent differences in any of these hormone concentrations between the azoospermic and oligozoospermic groups. Recovery of sperm density to baseline levels or above 20 x 10(6)/mL was significantly slower in the azoospermic group. During the recovery phase, the azoospermic men exhibited significantly higher LH and FSH levels compared to baseline and to the oligozoospermic subjects even though no differences in circulating T, E2, or IN were observed. We conclude that incomplete gonadotrophin suppression or differences in sex steroid or inhibin levels are unlikely to be responsible for the maintenance of minor degrees of spermatogenesis in some men during TE administration. The rebound rise in gonadotrophins in azoospermic but not oligozoospermic responders during recovery may reflect a more profound degree of spermatogenic suppression in the former group.

Entities:  

Keywords:  Androgens; Biology; Clinical Research; Clinical Trials; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Male; Developed Countries; Endocrine System; Estradiol; Estrogens; Europe; Family Planning; Follicle Stimulating Hormone; Gonadotropins; Gonadotropins, Pituitary--changes; Hormones; Luteinizing Hormone; Male Contraception; Northern Europe; Physiology; Research Report; Reversibility; Spermatogenesis Blocking Agents; Studies; Testosterone; United Kingdom

Mesh:

Substances:

Year:  1993        PMID: 8325955     DOI: 10.1210/jcem.77.1.8325955

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  A role for nocturnal serum testosterone surge in regulating spermatogenesis in the adult non-human primate.

Authors:  R Suresh; N R Moudgal
Journal:  Endocrine       Date:  1995-07       Impact factor: 3.633

Review 2.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

Review 3.  Prospects for pharmacological male contraception.

Authors:  S A Matlin
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 4.  The Disappearing Sperms: Analysis of Reports Published Between 1980 and 2015.

Authors:  Pallav Sengupta; Sulagna Dutta; Elzbieta Krajewska-Kulak
Journal:  Am J Mens Health       Date:  2016-04-19

Review 5.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

8.  The question of declining sperm density revisited: an analysis of 101 studies published 1934-1996.

Authors:  S H Swan; E P Elkin; L Fenster
Journal:  Environ Health Perspect       Date:  2000-10       Impact factor: 9.031

9.  Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols.

Authors:  Naoko Sato; Tomonobu Hasegawa; Yukihiro Hasegawa; Osamu Arisaka; Keiichi Ozono; Shin Amemiya; Toru Kikuchi; Hiroyuki Tanaka; Shohei Harada; Ichiro Miyata; Toshiaki Tanaka
Journal:  Clin Pediatr Endocrinol       Date:  2015-05-15

10.  Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception.

Authors:  Olayiwola O Oduwole; Natalia Vydra; Nicholas E M Wood; Luna Samanta; Laura Owen; Brian Keevil; Mandy Donaldson; Kikkeri Naresh; Ilpo T Huhtaniemi
Journal:  FASEB J       Date:  2014-03-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.